Advertisement

FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancer

      Abstract

      Immune checkpoint inhibitors (ICI) have high efficacy in metastatic colorectal cancer (mCRC) with microsatellite instability (MSI) but not in microsatellite stable (MSS) tumour due to the low tumour mutational burden. Selective internal radiation therapy (SIRT) could enhance neoantigen production thus triggering systemic anti-tumoral immune response (abscopal effect). In addition, Oxalipatin can induce immunogenic cell death and Bevacizumab can decrease the exhaustion of tumour infiltrating lymphocyte. In combination, these treatments could act synergistically to sensitize MSS mCRCs to ICI
      SIRTCI is a prospective, multicentre, open-label, phase II, non-comparative single-arm study evaluating the efficacy and safety of SIRT plus Xelox, Bevacizumab and Atezolizumab (anti-programmed death-ligand 1) in patients with liver-dominant MSS mCRC. The primary objective is progression-free survival at 9 months. The main inclusion criteria are patients with MSS mCRC with liver-dominant disease, initially unresectable disease and with no prior oncologic treatment for metastatic disease. The trial started in November 2020 and has included 10 out of the 52 planned patients.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Stewart C.L.
        • Warner S.
        • Ito K.
        • et al.
        Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?.
        Curr Probl Surg. 2018; 55: 330-379
        • Saltz L.B.
        • Clarke S.
        • Díaz-Rubio E.
        • et al.
        Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
        J Clin Oncol. 2008; 26: 2013-2019
        • Venook A.P.
        • Niedzwiecki D.
        • Lenz H.J.
        • et al.
        Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with kras wild-type advanced or metastatic colorectal cancer: a randomized clinical trial.
        JAMA. 2017; 317: 2392-2401
        • Heinemann V.
        • von Weikersthal L.F.
        • Decker T.
        • et al.
        FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
        Lancet Oncol. 2014; 15: 1065-1075
        • Loupakis F.
        • Cremolini C.
        • Masi G.
        • et al.
        Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
        N Engl J Med. 2014; 371: 1609-1618
        • Gruenberger T.
        • Bridgewater J.
        • Chau I.
        • et al.
        Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
        Ann Oncol. 2015; 26: 702-708
        • Strickler J.H.
        • Hurwitz H.I.
        Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer.
        Oncologist. 2012; 17: 513-524
        • Mocellin S.
        • Pasquali S.
        • Nitti D.
        Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer.
        Cochrane Database Syst Rev. 2009; CD007823
        • Pernot S.
        • Pellerin O.
        • Mineur L.
        • et al.
        Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49.
        Dig Liver Dis. 2022; : S1590-S8658
        • van Hazel G.A.
        • Heinemann V.
        • Sharma N.K.
        • et al.
        SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer.
        J Clin Oncol. 2016; 34: 1723-1731
        • Wasan H.S.
        • Gibbs P.
        • Sharma N.K.
        • et al.
        First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-global): a combined analysis of three multicentre, randomised, phase 3 trials.
        Lancet Oncol. 2017; 18: 1159-1171
        • André T.
        • Shiu K.K.
        • Kim T.W.
        • et al.
        Pembrolizumab in microsatellite-instability-high advanced colorectal cancer.
        N Engl J Med. 2020; 383: 2207-2218
        • Postow M.A.
        • Callahan M.K.
        • Barker C.A.
        • et al.
        Immunologic correlates of the abscopal effect in a patient with melanoma.
        N Engl J Med. 2012; 366: 925-931
        • Weichselbaum R.R.
        • Liang H.
        • Deng L.
        • et al.
        Radiotherapy and immunotherapy: a beneficial liaison?.
        Nat Rev Clin Oncol. 2017; 14: 365-379
        • Demaria S.
        • Formenti S.C.
        Radiotherapy effects on anti-tumor immunity: implications for cancer treatment.
        Front Oncol. 2013; 3: 128
        • Seyedin S.N.
        • Schoenhals J.E.
        • Lee D.A.
        • et al.
        Strategies for combining immunotherapy with radiation for anticancer therapy.
        Immunotherapy. 2015; 7: 967-980
        • Hiniker S.M.
        • Chen D.S.
        • Knox S.J.
        Abscopal effect in a patient with melanoma.
        N Engl J Med. 2012; 366: 2035
        • Tang C.
        • Welsh J.W.
        • de Groot P.
        • et al.
        Ipilimumab with stereotactic ablative radiation therapy: phase I results and immunologic correlates from peripheral T cells.
        Clin Cancer Res. 2017; 23: 1388-1396
        • Segal N.H.
        • Cercek A.
        • Ku G.
        • et al.
        Phase II single-arm study of durvalumab and tremelimumab with concurrent radiotherapy in patients with mismatch repair-proficient metastatic colorectal cancer.
        Clin Cancer Res. 2021; 27: 2200-2208
        • Hendlisz A.
        • Van den Eynde M.
        • Peeters M.
        • et al.
        Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.
        J Clin Oncol. 2010; 28: 3687-3694
        • Ghodadra A.
        • Bhatt S.
        • Camacho J.C.
        • et al.
        Abscopal effects and yttrium-90 radioembolization.
        Cardiovasc Intervent Radiol. 2016; 39: 1076-1080
        • Manning E.A.
        • Ullman J.G.
        • Leatherman J.M.
        • et al.
        A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism.
        Clin Cancer Res. 2007; 13: 3951-3959
        • Shrimali R.K.
        • Yu Z.
        • Theoret M.R.
        • et al.
        Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.
        Cancer Res. 2010; 70: 6171-6180
        • Roland C.L.
        • Lynn K.D.
        • Toombs J.E.
        • et al.
        Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer.
        PLoS ONE. 2009; 4: e7669
        • Wallin J.J.
        • Bendell J.C.
        • Funke R.
        • et al.
        Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.
        Nat Commun. 2016; 7: 12624
        • Pfirschke C.
        • Engblom C.
        • Rickelt S.
        • et al.
        Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy.
        Immunity. 2016; 44: 343-354
        • Mettu N.B.
        • Niedzwiecki D.
        • Boland P.M.
        • et al.
        BACCI: a phase II randomized, double-blind, placebo-controlled study of capecitabine bevacizumab plus atezolizumab versus capecitabine bevacizumab plus placebo in patients with refractory metastatic colorectal cancer.
        Ann. Oncol. 2019; 30: v203
        • Lieu C.
        • Bendell J.
        • Powderly J.D.
        • et al.
        Safety and combination of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or chemotherapy (chemo) in patients (pts) with locally advanced or metastatic solid tumors.
        Ann Oncol. 2014; 25: iv361
        • Seymour L.
        • Bogaerts J.
        • Perrone A.
        • et al.
        RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
        Lancet Oncol. 2017; 18: e143-e152
        • Dhir M.
        • Zureikat A.H.
        ASO Author Reflections: hepatic artery infusion (HAI) chemotherapy is associated with improved survival compared with radioembolization (Y90) in patients with isolated unresectable colorectal liver metastases.
        Ann Surg Oncol. 2018; 25: 782-783
        • Cercek A.
        • Gendel V.
        • Jabbour S.
        • et al.
        A comparison of yttrium-90 microsphere radioembolization to hepatic arterial infusional chemotherapy for patients with chemo-refractory hepatic colorectal metastases.
        Curr Treat Options Oncol. 2017; 18: 42
        • Segal N.H.
        • Cercek A.
        • Ku G.
        • et al.
        Phase II single-arm study of durvalumab and tremelimumab with concurrent radiotherapy in patients with mismatch repair-proficient metastatic colorectal cancer.
        Clin Cancer Res. 2021; 27: 2200-2208
        • Cremolini C.
        • Rossini D.
        • Antoniotti C.
        • et al.
        LBA20 FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: results of the phase II randomized AtezoTRIBE study by GONO.
        Ann. Oncol. 2021; 2: S1294-S1295
        • Edeline J.
        • Touchefeu Y.
        • Guiu B.
        • et al.
        Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial.
        JAMA Oncol. 2020 Jan 1; 6: 51-59
        • Mulcahy M.F.
        • Mahvash A.
        • Pracht M.
        • et al.
        Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase iii trial.
        J Clin Oncol. 2021; 39: 3897-3907
        • Gong J.
        • Wang C.
        • Lee P.P.
        • et al.
        Response to PD-1 blockade in microsatellite stable metastatic colorectal cancer harboring a POLE mutation.
        J Natl Compr Canc Netw. 2017; 15: 142-147
        • Tanis E.
        • Julié C.
        • Emile J.F.
        • et al.
        Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983.
        Eur J Cancer. 2015; 51: 2708-2717
        • Cabel L.
        • Riva F.
        • Servois V.
        • et al.
        Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study.
        Ann Oncol. 2017; 28: 1996-2001
        • Freshwater T.
        • Kondic A.
        • Ahamadi M.
        • et al.
        Evaluation of dosing strategy for pembrolizumab for oncology indications.
        J Immunother Cancer. 2017; 5: 43
        • Mehta R.
        • Cai K.
        • Kumar N.
        • et al.
        A Lesion-Based Response Prediction Model Using Pretherapy PET/CT Image Features for Y90 Radioembolization to Hepatic Malignancies.
        Technol Cancer Res Treat. 2017; 16: 620-629
        • Viaud S.
        • Saccheri F.
        • Mignot G.
        • et al.
        The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide.
        Science. 2013; 342: 971-976
        • Gopalakrishnan V.
        • Spencer C.N.
        • Nezi L.
        • et al.
        Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.
        Science. 2018; 359: 97-103
        • Routy B.
        • Le Chatelier E.
        • Derosa L.
        • et al.
        Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
        Science. 2018; 359: 91-97